Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $2,142,217.12 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 39,656 shares of the business’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $54.02, for a total transaction of $2,142,217.12. Following the transaction, the director now directly owns 188,981 shares of the company’s stock, valued at approximately $10,208,753.62. This represents a 17.34 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Mona Ashiya also recently made the following trade(s):

• On Friday, March 21st, Mona Ashiya sold 10,011 shares of Disc Medicine stock. The shares were sold at an average price of $54.00, for a total transaction of $540,594.00.
• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The stock was sold at an average price of $54.45, for a total transaction of $4,529,259.90.
• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The stock was sold at an average price of $54.29, for a total transaction of $10,974,506.34.

Disc Medicine Trading Down 1.9 %

Shares of NASDAQ IRON opened at $52.24 on Monday. Disc Medicine, Inc. has a 12 month low of $25.60 and a 12 month high of $68.73. The firm has a market capitalization of $1.81 billion, a PE ratio of -13.13 and a beta of 0.73. The firm has a fifty day simple moving average of $55.26 and a two-hundred day simple moving average of $56.11.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.08. On average, sell-side analysts predict that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IRON. Sterling Capital Management LLC increased its stake in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after acquiring an additional 503 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Disc Medicine in the 4th quarter worth about $40,000. Tower Research Capital LLC TRC increased its stake in shares of Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after acquiring an additional 266 shares in the last quarter. Quest Partners LLC bought a new position in shares of Disc Medicine in the 3rd quarter worth about $131,000. Finally, Quantbot Technologies LP bought a new position in shares of Disc Medicine in the 3rd quarter worth about $146,000. 83.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have commented on IRON. Stifel Nicolaus boosted their price target on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Morgan Stanley reissued an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a research note on Friday, March 7th. Wedbush reissued an “outperform” rating and issued a $90.00 price target (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. HC Wainwright reaffirmed a “buy” rating and issued a $118.00 price objective on shares of Disc Medicine in a research note on Tuesday, January 21st. Finally, TD Cowen assumed coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating for the company. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Disc Medicine presently has a consensus rating of “Buy” and an average price target of $93.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.